RJA
EDIT icon

Raymond James & Associates’s Editas Medicine EDIT Stock Holding History

Raymond James & Associates’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-34,100
Closed -$89K – 4070
2022
Q1 		$89K Buy
+34,100
New +$634K ﹤0.01% 3847
2021
Q3 		– Sell
-32,100
Closed -$562K – 4161
2021
Q2 		$562K Buy
32,100
+1,900
+6% +$70.2K ﹤0.01% 3000
2021
Q1 		$56K Buy
+30,200
New +$1.72M ﹤0.01% 3843

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's EDIT Position: Q3 2024 in Review

Raymond James & Associates increased its Editas Medicine (EDIT) stake by 6.6% in Q3 2024, buying an estimated $150K and bringing the position to 561,371 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

Raymond James & Associates first reported a position in EDIT in Q1 2018 and has held it in 27 quarters since. The position peaked at $4.3M in Q4 2020. 229 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Raymond James & Associates held 561,371 shares of Editas Medicine worth $1.91M as of Q3 2024.
  • Raymond James & Associates bought 34,556 Editas Medicine shares in Q3 2024, an estimated $150K.
  • Editas Medicine made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2251 holding.
  • Raymond James & Associates first reported a position in Editas Medicine in Q1 2018 and has held it in 27 quarters since.
  • Raymond James & Associates's Editas Medicine position peaked at $4.3M in Q4 2020.
  • 229 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.